Previous 10 | Next 10 |
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR ...
Montrouge, France, June 8, 2023 DBV Technologies to Participate i n Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming particip...
2023-05-16 08:30:17 ET Modular Medical ( MODD ) -24% . Eloxx Pharmaceuticals ELOX -22% after Q1 earning release . LM Funding America ( LMFA ) -18% . Horizon Therapeutics Public Limited Company HZNP -18% reports FTC preparing suit to block Amgen de...
2023-05-11 15:31:03 ET Shares of DBV Technologies (NASDAQ: DBVT) were up 14.5% early Thursday afternoon after the New England Journal of Medicine published phase 3 data on DBV's trial on its peanut allergy therapy for children aged one to three. The biotech company's shares ...
2023-05-10 18:18:51 ET Gainers: Purple Innovation ( PRPL ) +25% . DBV Technologies ( DBVT ) +24% . KLX Energy Services Holdings ( KLXE ) +23% . Digimarc Corporation ( DMRC ) +18% . Applovin Corporation ( APP ) +13% . Losers...
Montrouge, France, May 10, 2023 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial D ata E valuating Viaskin™ Peanut in Toddlers Th e New England Journal of Medicine (NEJM) pu...
2023-05-04 17:40:03 ET DBV Technologies press release ( NASDAQ: DBVT ): Q1 GAAP EPS of -$0.22. Revenue of $2.2M (-12.0% Y/Y). For further details see: DBV Technologies GAAP EPS of -$0.22, revenue of $2.2M
Montrouge, France, May 4, 2023 DBV Tech nolo gies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and cash equivalents of $192.3 million . DBV Technologies (Euronext: DBV – ISIN: FR0010417345 ...
2023-04-28 08:29:31 ET TOP Financial Group ( TOP ) +272% brokerage TOP Financial sees stock soar 195%. AGBA Group Holding ( AGBA ) +75% . Golden Sun Education Group ( GSUN ) +63% . Intelligent Living Application ( ILAG ) +59%...
Montrouge, France, April 19, 2023 D BV Technologies Outlin es Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the Company’s Phase 3 EPITOPE study met the pre-specif...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...